Wound Care Biologics Market Outlook:
Wound Care Biologics Market size was valued at USD 2.08 billion in 2025 and is set to exceed USD 3.49 billion by 2035, registering over 5.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of wound care biologics is estimated at USD 2.18 billion.
The rising cases of chronic wounds such as ischemic ulcers and foot ulcers among diabetic patients are driving the market growth. According to a 2023 report by the Journal of the American Medical Association (JAMA), annually 18.6 million people worldwide suffer from foot ulcers with 1.6 million cases reported in the United States.
Significant advancements in clinical wound management and their pathophysiology, coupled with ongoing biomedical innovations have resulted in a shift from invasive skin grafting techniques to dermal fibroblasts. Several pharmaceutical companies are focused on the research and development of cutting-edge biologics to diversify their product offerings. For instance, in June 2021 Mallinckrodt launched StrataGraft, a FDA-approved allogeneic cellularized scaffold. It consists of dermal fibroblasts in murine collagen and allogeneic cultured keratinocytes that eliminate the need for autografting in chronic burn patients.
